Douchet Gaëlle, Aspeslagh Sandrine
Université Paris-Saclay, Gustave-Roussy Cancer Centre, Drug Development Department (DITEP), 94805 Villejuif, France.
Université Paris-Saclay, Gustave-Roussy Cancer Centre, Drug Development Department (DITEP), 94805 Villejuif, France.
Bull Cancer. 2017 May;104(5):485-493. doi: 10.1016/j.bulcan.2017.03.008. Epub 2017 Apr 19.
Immune checkpoint blockade by the use of anti-PD(L)1 or anti-CTLA4 antibodies can induce long lasting disease response and maybe cure in a lot of advanced cancer patients. This ongoing immunotherapy revolution has given new hope to cancer patients and oncologists. However, still the majority of cancer patients do not respond to immune checkpoint blockade and novel therapeutical possibilities are being tested in several clinical trials. One of the possibilities to enhance responses to immune checkpoint blockade is the combination with chemotherapy or with other immune checkpoint blockade molecules. In this review, we explore the preclinical rational for this synergism and the potential consequences for immunotherapy in oncology.
使用抗PD(L)1或抗CTLA4抗体进行免疫检查点阻断可诱导持久的疾病反应，甚至可能治愈许多晚期癌症患者。这场正在进行的免疫治疗革命给癌症患者和肿瘤学家带来了新希望。然而，仍有大多数癌症患者对免疫检查点阻断无反应，目前正在多项临床试验中测试新的治疗可能性。增强对免疫检查点阻断反应的一种可能性是与化疗或其他免疫检查点阻断分子联合使用。在本综述中，我们探讨了这种协同作用的临床前理论依据以及对肿瘤免疫治疗的潜在影响。
